New Dual-Action shot could tame PCOS symptoms

NCT ID NCT07616037

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new weekly injection called HEC88473 in 30 women with polycystic ovary syndrome (PCOS). The drug targets two pathways to improve hormone levels and menstrual cycles. Researchers will track changes in free androgen index and menstrual regularity over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HEC88473 (a GLP-1/FGF21 dual agonist)
What this could lead to: If successful, this could offer a new treatment option for PCOS that improves hormone balance and menstrual regularity.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug may cause side effects or fail to show clear benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PCOS (POLYCYSTIC OVARY SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PCOS (POLYCYSTIC OVARY SYNDROME)

Contacts and locations

Locations

Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 201508, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.